PFE Mar 2023 37.500 put
| Previous Close | 0.8700 |
| Open | 0.8500 |
| Bid | 0.9200 |
| Ask | 1.1200 |
| Strike | 37.50 |
| Expire Date | 2023-03-17 |
| Day's Range | 0.8500 - 0.9300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 111 |
- Yahoo Finance
Moderna CEO faces Sen. Sanders in COVID-19 vaccine pricing hearing Wednesday
Moderna CEO Stéphane Bancel is set to face Sen. Bernie Sanders to defend the company's fast growth and planned price hike of its COVID-19 vaccine.
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
NEW YORK, March 21, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2023 Performance Report, to be issued that morning.
- Motley Fool
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.
